Last reviewed · How we verify
GENISTEIN
Genistein is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | GENISTEIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Constipation
- Dyspepsia
- Abdominal Pain
- Vomiting
- Epigastric Pain
Key clinical trials
- PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition (PHASE2)
- Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy (NA)
- A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease (PHASE2)
- Effectiveness of Genistein in Mild Cognitive Impairment (NA)
- Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study (PHASE2)
- Phase 1 BIO 300 Oral Suspension (PHASE1)
- Evaluating Metabolic and Anti-inflammatory Effect of Genistein on Post-myocardial Infarction Patients (NA)
- Exploring a Natural Solution for Childhood Obesity (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GENISTEIN CI brief — competitive landscape report
- GENISTEIN updates RSS · CI watch RSS